ID: h-89f2d5ab82
Hypothesis
Mitochondrial-Targeted PINK1/Parkin Pathway Activation for Neuroprotection
PINK1 loss-of-function prevents Parkin recruitment to damaged mitochondria, blocking mitophagy.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
PINK1 loss-of-function prevents Parkin recruitment to damaged mitochondria, blocking mitophagy. Urolithin A is proposed as a mitochondrial-targeted activator. Major limitations include urolithin A's lack of specificity for the PINK1/Parkin pathway (induces general autophagy via PGC-1α/AMPK/Nrf2), failure of PINK1 knockout mice to recapitulate human PD phenotype, and uncertain applicability to idiopathic PD when PINK1/PRKN mutations cause only ~2-3% of cases.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["PINK1<br/>Serine/Threonine Kinase"]
B["PRKN (Parkin)<br/>E3 Ubiquitin Ligase"]
C["Mitochondrial<br/>Membrane Depolarization"]
D["PINK1<br/>Accumulation"]
E["Parkin<br/>Recruitment"]
F["Mitophagy<br/>Receptor"]
G["Dopaminergic<br/>Neuron Survival"]
H["PD<br/>Pathogenesis"]
A --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Supports
PINK1-deficient flies show mitochondrial dysfunction rescued by Parkin overexpression
Contradicts
Urolithin A activates general autophagy, not specifically PINK1/Parkin pathway
Contradicts
PINK1 knockout mice do not show robust dopaminergic neuron loss seen in humans
Contradicts
PINK1/Parkin mutations cause <2% of PD—limited applicability to idiopathic PD
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — PINK1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for PINK1/PRKN from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PINK1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0224
Events (7d)
0
Price History
▲0.8%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF Urolithin A (10 μM, 24-72h) requires the PINK1/Parkin pathway to exert neuroprotective effects, THEN PINK1 knockout SH-SY5Y cells treated with urolithin A will show no significant reduction in Mito | PINK1 knockout cells will retain ≥90% baseline mitochondrial ROS levels and caspase-3 activity after urolithin A treatment, while wild-type cells will show ≥40% | — no observation — | pending | 0.35 |
| IF urolithin A's neuroprotective effects generalize beyond PINK1/PRKN mutation carriers, THEN in an idiopathic Parkinson's disease (non-familial) iPSC-derived neuron model, chronic urolithin A treatme | Idiopathic PD neurons treated with urolithin A will show ≥30% reduction in phospho-α-synuclein (Ser129) fluorescence intensity and ≥25% improvement in mitochond | — no observation — | pending | 0.25 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF Urolithin A (10 μM, 24-72h) requires the PINK1/Parkin pathway to exert neuroprotective effects, THEN PINK1 knockout SH-SY5Y cells treated with urolithin A will show no significant reduction in MitoSox fluorescence (mitochondrial ROS) or caspase-3 activation compared to vehicle control within 72 h
Predicted outcome: PINK1 knockout cells will retain ≥90% baseline mitochondrial ROS levels and caspase-3 activity after urolithin A treatment, while wild-type cells will
Falsification: Urolithin A significantly reduces mitochondrial ROS (≥40%) and caspase-3 activation (≥40%) in PINK1 knockout cells, indicating PINK1-independent neuroprotection
pendingconf 25%
IF urolithin A's neuroprotective effects generalize beyond PINK1/PRKN mutation carriers, THEN in an idiopathic Parkinson's disease (non-familial) iPSC-derived neuron model, chronic urolithin A treatment (5 μM, 14 days) will reduce α-synuclein aggregate burden by ≥30% compared to vehicle.
Predicted outcome: Idiopathic PD neurons treated with urolithin A will show ≥30% reduction in phospho-α-synuclein (Ser129) fluorescence intensity and ≥25% improvement in
Falsification: Urolithin A treatment in idiopathic PD neurons produces no significant reduction in α-synuclein aggregates (<15%) and no improvement in mitochondrial function, indicating the effect is specific to fam
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.